Sign in

    Joel Beatty

    Senior Research Analyst and MD at Robert W. Baird & Co.

    Joel Beatty is a Senior Research Analyst and MD at Robert W. Baird & Co., specializing in biotechnology equity research with coverage spanning leading companies such as Editas Medicine, PTC Therapeutics, Cogent Biosciences, e.l.f. Beauty, Sage Therapeutics, and ACADIA Pharmaceuticals. He maintains a strong performance track record, with approximately 54% of his price targets met and an average upside of 45% on recommendations, ranking among the top 5% of Wall Street analysts according to TipRanks. Beatty began his analyst career at Citigroup in 2012 before joining Baird in 2021, following experience as a practicing physician and principal at the American College of Preventive Medicine. He holds MD, MPH, and MBA degrees from the University at Buffalo, is board certified in Preventive Medicine, and has obtained recognized industry credentials including CFA certification.

    Joel Beatty's questions to Amylyx Pharmaceuticals (AMLX) leadership

    Joel Beatty's questions to Amylyx Pharmaceuticals (AMLX) leadership • Q3 2024

    Question

    Joel Beatty of Baird asked how the company thinks about balancing its remaining cash among its lead program avexitide, other pipeline assets with potentially lower success probabilities, and the potential for business development.

    Answer

    James Frates, Chief Financial Officer, emphasized that avexitide is the clear lead asset due to its strong data, safety, and late-stage development. He affirmed the company's cash runway extends into 2026, which is sufficient to get through the avexitide Phase III data readout. While prepared to tighten belts if needed, he stated current plans support all key programs and their upcoming milestones.

    Ask Fintool Equity Research AI

    Joel Beatty's questions to IDEAYA Biosciences (IDYA) leadership

    Joel Beatty's questions to IDEAYA Biosciences (IDYA) leadership • Q1 2022

    Question

    Joel Beatty asked at which dose levels the previously mentioned SAEs and the single Grade 3 AE occurred, and also sought confirmation on whether GSK would consider clinical response data in its opt-in decision.

    Answer

    Matt Maurer, Head of Clinical Oncology, stated the SAEs were related to malignancy progression and occurred across doses, while the Grade 3 asthenia event was at dose level four. CEO & President Yujiro Hata confirmed the formal option data package requirement concludes with pharmacodynamic data and does not include clinical response data.

    Ask Fintool Equity Research AI